Today’s Featured Stock
Valued at $9.5 million, Spyre Therapeutics (SYRE) is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.
What I’m Watching
I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals and superior current momentum. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. SYRE checks those boxes. The Trend Seeker issued a new “Buy” signal on June 4. Since then, the stock has gained 37.43%.
More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.
www.barchart.comBarchart’s Technical Indicators for Spyre Therapeutics
Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.
Spyre Therapeutics scored a 3-year high of $110.01 on Aug. 19.
Spyre has a Weighted Alpha of 412.53. SYRE has a 100% “Buy” opinion from Barchart. The stock has gained 569.49% over the past 52 weeks. Spyre has its Trend Seeker “Buy” signal intact. The stock recently traded at $108.71 with a 50-day moving average of $95.70. SYRE had 8 new highs and gained 8.61% in the last month. 60-month beta of 3.03. Relative Strength Index (RSI) is at 62.19. There’s a technical support level around $103.30.Don’t Forget the Fundamentals
$9.5 million market capitalization. Analysts have not given revenue and earnings guidance.Analyst and Investor Sentiment on Spyre Therapeutics
The Wall Street analysts followed by Barchart give the stock 16 “Strong Buy” and 2 “Hold” opinions with price targets between $97 and $135. Value Line rates the stock “Highest.” Morningstar thinks the stock is overvalued by 12% with a price target of $93.02. CFRAs MarketScope rates the stock as “Hold.” 2,910 investors are following the stock on Seeking Alpha, which rates it a “Hold.” TipRanks’ consensus price target is $124.73 for a 15.68% gain. Short interest is 13.81% of the float with 13.52 days to cover the float.The Bottom Line on Spyre Therapeutics
Although Spyre Therapeutics has a small following of individual investors, it appears Wall Street has discovered it and predicts upward momentum.
Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance.
On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.
More news from Barchart
This Stock’s Already Up Nearly 600% Over the Past Year Ahead of Alibaba Earnings, Here's What Barchart Data Says Comes Next for BABA Stock This Former Small-Cap Darling Is in Freefall, But I Like the Stock Here Deflated Microchip Technology Stock Could Target a Contrarian Move to $85